Dr Kathleen Rickard, MD, Chief Medical Officer, Verona Pharma discusses the burden of COPD and urgent need for a novel treatment.
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.
News & SEC Filings
Events & Presentations
© Verona Pharma plc 2022. All rights reserved